PolypDx uses a proprietary technology platform to detect adenomatous polyps. The test uses metabolite biomarkers to detect polyps before they become malignant.
“PolypDx can be integrated into the diagnostic process for colon cancer and lowers the overall costs incurred by a patient who would otherwise have to undergo a colonoscopy just to assess polyp presence,” said Frost & Sullivan Research Analyst Madhumitha Rangesa.
More articles on gastroenterology:
Dr. Nitesh Ratnakar elected West Virginia ACG governor
5 gastroenterologists leadership moves
5 statistics on gastroenterologist compensation, career satisfaction
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.